Astria Therapeutics (NASDAQ:ATXS) Sees Strong Trading Volume - What's Next?

Key Points

• Astria Therapeutics (NASDAQ:ATXS) experienced a **73% increase** in trading volume, with approximately **935,802 shares** traded on Wednesday, driving the stock price to **$11.88**.
• Analysts are divided on ATXS, with JMP Securities maintaining a "market perform" rating, while Jefferies and Oppenheimer downgraded their ratings, indicating a **consensus target price** of **$25.00** and a general classification of "Moderate Buy."
• Astria Therapeutics reported an earnings per share (EPS) of **($0.57)** for the last quarter, outperforming analysts' expectations of **($0.61)**, with projections indicating a potential EPS of **($1.65)** for the current year.

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) shares saw unusually-high trading volume on Wednesday . Approximately 935,802 shares were traded during trading, an increase of 73% from the previous session's volume of 541,514 shares.The stock last traded at $11.88 and had previously closed at $11.61.

Analyst Upgrades and Downgrades

ATXS has been the topic of several recent research reports. JMP Securities reaffirmed a "market perform" rating on shares of Astria Therapeutics in a report on Wednesday. Jefferies Financial Group lowered Astria Therapeutics from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $30.00 to $13.00 in a research report on Tuesday. Oppenheimer lowered Astria Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Tuesday. Citigroup reissued an "outperform" rating on shares of Astria Therapeutics in a research report on Wednesday, August 13th. Finally, HC Wainwright lifted their price objective on Astria Therapeutics from $16.00 to $20.00 and gave the stock a "buy" rating in a research report on Wednesday, September 17th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $25.00.

Astria Therapeutics Trading Up 2.6%

The firm has a market capitalization of $672.48 million, a P/E ratio of -5.93 and a beta of 0.43. The business has a 50-day moving average of $7.23 and a 200 day moving average of $5.94.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) EPS for the quarter, beating analysts' consensus estimates of ($0.61) by $0.04. As a group, research analysts forecast that Astria Therapeutics, Inc. will post -1.65 EPS for the current year.

Institutional Trading of Astria Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ATXS. GAMMA Investing LLC increased its holdings in Astria Therapeutics by 1,127.4% during the 1st quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company's stock worth $46,000 after purchasing an additional 7,971 shares in the last quarter. Corton Capital Inc. purchased a new position in shares of Astria Therapeutics in the 1st quarter worth approximately $72,000. Nuveen LLC purchased a new position in shares of Astria Therapeutics in the 1st quarter worth approximately $553,000. Fox Run Management L.L.C. purchased a new position in shares of Astria Therapeutics in the 1st quarter worth approximately $183,000. Finally, American Century Companies Inc. boosted its stake in shares of Astria Therapeutics by 22.1% in the 1st quarter. American Century Companies Inc. now owns 52,107 shares of the biotechnology company's stock worth $278,000 after buying an additional 9,414 shares during the last quarter. 98.98% of the stock is owned by institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.